UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study

HemaSphere, 2024-08, Vol.8 (8), p.e106-n/a

2024

Volltextzugriff (PDF)

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Blood, 2024-02, Vol.143 (8), p.734

2024

Volltextzugriff (PDF)

Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study

Haematologica (Roma), 2024-01, Vol.109 (1), p.325

2024

Volltextzugriff (PDF)

Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma

Haematologica (Roma), 2023-11, Vol.108 (11), p.3160-3164

2023

Volltextzugriff (PDF)

Immune thrombocytopenia purpura relapse presented by Jacuzzi sign

British journal of haematology, 2023-08, Vol.202 (4), p.711-711

2023

Volltextzugriff (PDF)

CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment

EJHaem, 2022-08, Vol.3 (3), p.970-974

2022

Volltextzugriff (PDF)

Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patients

British journal of haematology, 2022-06, Vol.197 (6), p.728-735

2022

Volltextzugriff (PDF)

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Bone marrow transplantation (Basingstoke), 2022-03, Vol.57 (3), p.499-501

2022

Volltextzugriff (PDF)

Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital

Blood cancer journal (New York), 2021-07, Vol.11 (7), p.129-129, Article 129

2021

Volltextzugriff (PDF)

Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases

Haematologica (Roma), 2021-07, Vol.106 (7), p.2034-2036

2021

Volltextzugriff (PDF)

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

The Lancet. Haematology, 2021-05, Vol.8 (5), p.e355-e364

2021

Volltextzugriff (PDF)

Thiotepa intrathecal injections for myelomatous central nervous system involvement

British journal of haematology, 2021-04, Vol.193 (2), p.e9-e12

2021

Volltextzugriff (PDF)

Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma

Hematological oncology, 2020-10, Vol.38 (4), p.517-522

2020

Volltextzugriff (PDF)

Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study

Annals of hematology, 2020-07, Vol.99 (7), p.1615-1625

2020

Volltextzugriff (PDF)

Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma

British journal of haematology, 2020-05, Vol.189 (3), p.e73-e76

2020

Volltextzugriff (PDF)

Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature

British journal of haematology, 2020-01, Vol.188 (2), p.338-340

2020

Volltextzugriff (PDF)

Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?

British journal of haematology, 2018-01, Vol.180 (2), p.304-308

2018

Volltextzugriff (PDF)

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

Leukemia & lymphoma, 2016-12, Vol.57 (12), p.2820-2826

2016

Volltextzugriff (PDF)

Rituximab‐ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy

British journal of haematology, 2016-11, Vol.175 (4), p.735-737

2016

Volltextzugriff (PDF)

Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment

Leukemia & lymphoma, 2016-10, Vol.57 (10), p.2425-2428

2016

Volltextzugriff (PDF)

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis

Haematologica (Roma), 2015-11, Vol.100 (11), p.e471-e474

2015

Volltextzugriff (PDF)

Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma

Haematologica (Roma), 2015-07, Vol.100 (7), p.e269-e271

2015

Volltextzugriff (PDF)

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure

Leukemia research, 2015-05, Vol.39 (5), p.501-504

2015

Volltextzugriff (PDF)

Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases

British journal of haematology, 2015-03, Vol.168 (5), p.671-678

2015

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

ThemaHematology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Humans
(24)
Female
(16)
Male
(16)
Aged
(11)
Middle Aged
(11)
Adult
(9)
Retrospective Studies
(9)
Aged, 80 And Over
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Biological And Medical Sciences
(7)
Hematologic And Hematopoietic Diseases
(7)
Life Sciences
(7)
Medical Sciences
(7)
Multiple Myeloma
(7)
Oncology
(7)
Treatment Outcome
(7)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(6)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study

Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma

Immune thrombocytopenia purpura relapse presented by Jacuzzi sign

CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment

Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patients

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital

Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Thiotepa intrathecal injections for myelomatous central nervous system involvement

Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma

Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study

Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma

Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature

Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies

Rituximab‐ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy

Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis

Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure

Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases

Aktive Filter

Suchergebnisse filtern